CY1110512T1 - Πολυκυκλοαλκυλοπουρινες ως ανταγωνιστες υποδοχεων αδενοσινης - Google Patents

Πολυκυκλοαλκυλοπουρινες ως ανταγωνιστες υποδοχεων αδενοσινης

Info

Publication number
CY1110512T1
CY1110512T1 CY20091100543T CY091100543T CY1110512T1 CY 1110512 T1 CY1110512 T1 CY 1110512T1 CY 20091100543 T CY20091100543 T CY 20091100543T CY 091100543 T CY091100543 T CY 091100543T CY 1110512 T1 CY1110512 T1 CY 1110512T1
Authority
CY
Cyprus
Prior art keywords
polycyclocoylypurines
competitives
receptor
disorders
adenosine
Prior art date
Application number
CY20091100543T
Other languages
English (en)
Inventor
William F Kiesman
James E Dowling
Carol L Ensinger
Gnanasambandam Kumaravel
Russell C Petter
Ko Chung Lin
He Xi Chang
Original Assignee
Biogen Idec Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma Inc. filed Critical Biogen Idec Ma Inc.
Publication of CY1110512T1 publication Critical patent/CY1110512T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Η εφεύρεση βασίζεται στην ανακάλυψη ότι ενώσεις του Χημικού Τύπου I είναι αναπάντεχα σε μεγάλο βαθμό ισχυροί και επιλεκτικοί αναστολείς συγκεκριμένων υποτύπων υποδοχέων αδενοσίνης Α1. Ανταγωνιστές της αδενοσίνης Α1 μπορεί να είναι χρήσιμοι στην πρόληψη και/ή θεραπεία πολυάριθμων νόσων, όπου συμπεριλαμβάνονται καρδιακές και κυκλοφοριακές διαταραχές, εκφυλιστικές διαταραχές του κεντρικού νευρικού συστήματος, αναπνευστικές διαταραχές και πολλές νόσοι για τις οποίες είναι κατάλληλη μία διουρητική θεραπεία. Σε μία ενσωμάτωση εφεύρεση προβάλει μία ένωση του χημικού τύπου I:
CY20091100543T 1999-11-12 2009-05-21 Πολυκυκλοαλκυλοπουρινες ως ανταγωνιστες υποδοχεων αδενοσινης CY1110512T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16519199P 1999-11-12 1999-11-12
EP00978546A EP1230243B1 (en) 1999-11-12 2000-11-13 Poycyloalkylpurines as adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
CY1110512T1 true CY1110512T1 (el) 2015-04-29

Family

ID=22597852

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100543T CY1110512T1 (el) 1999-11-12 2009-05-21 Πολυκυκλοαλκυλοπουρινες ως ανταγωνιστες υποδοχεων αδενοσινης

Country Status (35)

Country Link
US (5) US6649600B1 (el)
EP (3) EP2070930A1 (el)
JP (1) JP2003513982A (el)
KR (2) KR100863761B1 (el)
CN (2) CN100390178C (el)
AT (1) ATE424403T1 (el)
AU (1) AU784556B2 (el)
BG (1) BG65720B1 (el)
BR (1) BR0015545A (el)
CA (1) CA2390496A1 (el)
CY (1) CY1110512T1 (el)
CZ (1) CZ20021614A3 (el)
DE (1) DE60041710D1 (el)
DK (1) DK1230243T3 (el)
EA (1) EA005211B1 (el)
EE (1) EE05365B1 (el)
ES (1) ES2323357T3 (el)
GE (1) GEP20043303B (el)
HK (1) HK1049155B (el)
IL (1) IL149487A0 (el)
IS (1) IS6379A (el)
ME (1) MEP42208A (el)
MX (1) MXPA02004796A (el)
NO (1) NO328956B1 (el)
NZ (2) NZ527917A (el)
PL (1) PL206890B1 (el)
PT (1) PT1230243E (el)
RS (1) RS50381B (el)
SI (1) SI1230243T1 (el)
SK (1) SK287311B6 (el)
TR (1) TR200201260T2 (el)
TW (1) TWI272270B (el)
UA (1) UA77391C2 (el)
WO (1) WO2001034610A1 (el)
ZA (1) ZA200203701B (el)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20043303B (en) * 1999-11-12 2004-01-12 Biogen Idec Inc Polycycloalkylpurines as Adenosine Receptor Antagonists
DK1230241T3 (da) * 1999-11-12 2007-06-04 Biogen Idec Inc Adenosinreceptorantagonister og fremgangsmåder til fremstilling og anvendelse af samme
UA80258C2 (en) * 2001-09-06 2007-09-10 Biogen Inc Methods of treating pulmonary disease
DE10145193C1 (de) 2001-09-13 2003-03-13 Sachtler Gmbh & Co Kg Körpermontierbares Kameratragesystem mit einem multifunktionalen Verbund elektrischer Komponenten
RS107404A (en) * 2002-06-12 2007-02-05 Biogen Idec Ma Inc., Method of treating ischemia perefusion injury using adenosine receptor antagonists
EP1521584A1 (en) 2002-06-17 2005-04-13 Glaxo Group Limited Purine derivatives as liver x receptor agonists
US20040106797A1 (en) * 2002-07-19 2004-06-03 Pascal Druzgala Novel xanthines having adenosine A1-receptor antagonist properties
CA2516250A1 (en) 2003-02-19 2004-09-02 Endacea, Inc. A1 adenosine receptor antagonists
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
MXPA05011371A (es) * 2003-04-25 2005-12-01 Novacardia Inc Metodo para mejorar la diuresis en individuos con la funcion renal deteriorada.
WO2005009343A2 (en) 2003-06-06 2005-02-03 Endacea, Inc. A1 adenosine receptor antogonists
BRPI0611966B1 (pt) 2005-06-17 2022-05-03 Apogee Biotechnology Corporation Composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica os compreendendo
WO2007059330A2 (en) * 2005-11-17 2007-05-24 Medkura Inc. Cubane nucleoside analogs
JP2009532479A (ja) * 2006-04-06 2009-09-10 ノヴァカーディア，インク． アデノシンａ１受容体アンタゴニストと抗痙攣薬の同時投与
CN101085785B (zh) * 2006-06-06 2011-09-21 中国科学院上海药物研究所 用于治疗乙型肝炎的嘌呤类化合物及其制备方法和用途，以及包括该化合物的组合物
EP2035009A1 (en) * 2006-06-16 2009-03-18 Novacardia, Inc. Prolonged improvement of renal function comprising infrequent administration of an aa1ra
EP2048944A4 (en) * 2006-07-17 2012-06-27 Tyratech Inc COMPOSITIONS AND METHODS FOR CONTROLLING INSECTS
US20080242684A1 (en) * 2007-03-29 2008-10-02 Howard Dittrich Methods of administration of adenosine a1 receptor antagonists
WO2008121893A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
JP5603248B2 (ja) 2007-12-21 2014-10-08 エンダセア， インコーポレイテッド Ａ１アデノシン受容体アンタゴニスト
US20100063071A1 (en) * 2008-06-13 2010-03-11 Kiesman William F Therapeutic compositions and related methods of use
WO2010011917A1 (en) * 2008-07-25 2010-01-28 Glaxosmithkline Llc SEH AND 11β-HSD1 DUAL INHIBITORS
WO2011063268A2 (en) 2009-11-19 2011-05-26 Biogen Idec Ma Inc Novel synthetic methods
CN102762625B (zh) * 2009-12-04 2014-06-18 联邦科学与工业研究组织 聚合材料
CN101709034B (zh) * 2009-12-14 2017-05-31 大连九信精细化工有限公司 双环[2.2.2]辛烷‑1，4‑二羧酸单甲酯的合成方法
TWI538905B (zh) * 2010-12-22 2016-06-21 Ｈ 朗德貝克公司 雙環［３．２．１］辛基醯胺衍生物及其用途
AU2012275499A1 (en) 2011-06-27 2013-12-19 Kyorin Pharmaceutical Co., Ltd. Bridged bicyclic compounds for the treatment of bacterial infections
US8962660B2 (en) 2013-03-14 2015-02-24 Bristol-Myers Squibb Company Oxabicyclo [2.2.2] acid GPR120 modulators
JP2016516708A (ja) * 2013-03-14 2016-06-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ビシクロ［２．２．２］酸のｇｐｒ１２０モジュレーター
LT6401B (lt) 2015-07-28 2017-06-12 Vilniaus Universitetas Karboanhidrazės selektyvūs inhibitoriai
CN109843846B (zh) 2016-10-19 2022-07-05 伊士曼化工公司 双环[2.2.2]辛烷的合成
US11548893B2 (en) 2017-07-15 2023-01-10 Arisan Therapeutics Inc. Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
TWI802591B (zh) 2017-09-14 2023-05-21 日商第一三共股份有限公司 具有環狀構造的化合物
WO2019075004A1 (en) 2017-10-11 2019-04-18 Eastman Chemical Company SYNTHESIS OF BICYCLO [2.2.2] OCTANE DERIVATIVES
ES2964964T3 (es) 2017-11-01 2024-04-10 Bristol Myers Squibb Co Compuestos bicíclicos puenteados como moduladores del receptor X farnesoide
KR20210060546A (ko) 2018-09-18 2021-05-26 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 옥사비시클로 산
US10836899B2 (en) 2018-12-13 2020-11-17 Eastman Chemical Company Polyesters with specified crystallization half-times

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0011399A1 (en) 1978-11-11 1980-05-28 FISONS plc N-substituted theophyllines, processes for their preparation and pharmaceutical compositions containing them
DE8817122U1 (el) 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 6507 Ingelheim, De
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
US5290782A (en) * 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
ES2152207T3 (es) 1989-10-20 2001-02-01 Kyowa Hakko Kogyo Kk Derivados condensados de la purina.
DE4019892A1 (de) 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
JPH0559056A (ja) * 1991-02-25 1993-03-09 Kyowa Hakko Kogyo Co Ltd キサンチン誘導体
JPH04270222A (ja) 1991-02-25 1992-09-25 Kyowa Hakko Kogyo Co Ltd 脳機能改善剤
CA2061544A1 (en) * 1991-02-25 1992-08-26 Fumio Suzuki Xanthine compounds
JPH04346986A (ja) 1991-05-23 1992-12-02 Kyowa Hakko Kogyo Co Ltd トリチウム標識化されたキサンチン誘導体
ATE180482T1 (de) * 1991-11-08 1999-06-15 Kyowa Hakko Kogyo Kk Xanthinderivate zur behandlung der demenz
JP3115128B2 (ja) * 1991-11-08 2000-12-04 協和醗酵工業株式会社 キサンチン誘導体
JPH05294966A (ja) * 1992-02-17 1993-11-09 Kyowa Hakko Kogyo Co Ltd キサンチン誘導体
US5342841A (en) * 1992-03-12 1994-08-30 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
JPH0616668A (ja) * 1992-03-12 1994-01-25 Kyowa Hakko Kogyo Co Ltd キサンチン誘導体
TW252044B (el) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
US5384176A (en) * 1992-12-11 1995-01-24 Zimmerman; Richard C. Phenolic acid sulfate esters for prevention of marine biofouling
WO1994016702A1 (en) * 1993-01-26 1994-08-04 Kyowa Hakko Kogyo Co., Ltd. Remedy for irregular bowel movement
US5395836A (en) * 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
JP3729874B2 (ja) * 1993-04-07 2005-12-21 協和醗酵工業株式会社 キサンチン誘導体
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
AU7675598A (en) 1997-06-16 1999-01-04 Kyowa Hakko Kogyo Co. Ltd. Hepatic edema remedy
AU7675498A (en) 1997-06-16 1999-01-04 Kyowa Hakko Kogyo Co. Ltd. Preventive and remedy for drug-induced nephropathy
DE19816857A1 (de) * 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO1999055339A1 (en) 1998-04-24 1999-11-04 Biogen, Inc. Adenosine a1 receptor antagonist containing composition and method for restoring diuretic and renal function
EP0955301A3 (en) * 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
US6489331B1 (en) 1998-07-02 2002-12-03 Kyowa Hakko Kogyo Co., Ltd. Remedies for diabetes
DK1230241T3 (da) * 1999-11-12 2007-06-04 Biogen Idec Inc Adenosinreceptorantagonister og fremgangsmåder til fremstilling og anvendelse af samme
GEP20043303B (en) * 1999-11-12 2004-01-12 Biogen Idec Inc Polycycloalkylpurines as Adenosine Receptor Antagonists
DE60304911D1 (de) 2002-02-25 2006-06-08 Eisai Co Ltd Xanthin-Derivate als DPP-IV-Inhibitoren
US20040106797A1 (en) * 2002-07-19 2004-06-03 Pascal Druzgala Novel xanthines having adenosine A1-receptor antagonist properties
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
CA2556073C (en) * 2004-02-14 2012-01-10 Smithkline Beecham Corporation 8-chloro-1,3-disubstituted xanthine derivatives as hm74a receptor modulators

Also Published As

Publication number Publication date
EP1230243A1 (en) 2002-08-14
ZA200203701B (en) 2004-02-23
EP2305684A1 (en) 2011-04-06
NO20022238L (no) 2002-07-12
UA77391C2 (en) 2006-12-15
HK1049155A1 (en) 2003-05-02
WO2001034610A1 (en) 2001-05-17
NO328956B1 (no) 2010-06-28
DK1230243T3 (da) 2009-06-15
TWI272270B (en) 2007-02-01
CN1402729A (zh) 2003-03-12
US20090221821A1 (en) 2009-09-03
IS6379A (is) 2002-05-10
DE60041710D1 (de) 2009-04-16
GEP20043303B (en) 2004-01-12
CN100390178C (zh) 2008-05-28
EP2070930A1 (en) 2009-06-17
US6649600B1 (en) 2003-11-18
HK1049155B (zh) 2009-11-06
AU784556B2 (en) 2006-05-04
EA005211B1 (ru) 2004-12-30
EP1230243B1 (en) 2009-03-04
MXPA02004796A (es) 2007-01-30
BG106762A (en) 2003-01-31
ES2323357T3 (es) 2009-07-14
TR200201260T2 (tr) 2002-09-23
KR20080027971A (ko) 2008-03-28
IL149487A0 (en) 2002-11-10
EE05365B1 (et) 2010-12-15
EE200200247A (et) 2003-06-16
SK6632002A3 (en) 2003-02-04
US7579354B2 (en) 2009-08-25
AU1600001A (en) 2001-06-06
NO20022238D0 (no) 2002-05-10
JP2003513982A (ja) 2003-04-15
ATE424403T1 (de) 2009-03-15
NZ519426A (en) 2003-08-29
PT1230243E (pt) 2009-06-12
YU33802A (sh) 2006-01-16
BR0015545A (pt) 2002-08-06
US20060252730A1 (en) 2006-11-09
US20070015732A1 (en) 2007-01-18
PL356033A1 (en) 2004-06-14
NZ527917A (en) 2005-03-24
CA2390496A1 (en) 2001-05-17
BG65720B1 (bg) 2009-08-31
CN101255162A (zh) 2008-09-03
MEP42208A (en) 2011-02-10
EA200200560A1 (ru) 2002-10-31
CZ20021614A3 (cs) 2002-07-17
KR20020049050A (ko) 2002-06-24
SK287311B6 (sk) 2010-06-07
RS50381B (sr) 2009-11-10
PL206890B1 (pl) 2010-10-29
KR100863761B1 (ko) 2008-10-16
US20040067966A1 (en) 2004-04-08
SI1230243T1 (sl) 2009-08-31

Similar Documents

Publication Publication Date Title
CY1110512T1 (el) Πολυκυκλοαλκυλοπουρινες ως ανταγωνιστες υποδοχεων αδενοσινης
CY1106560T1 (el) Ανταγωνιστες υποδοχεα αδενοσινης και μεθοδοι κατασκευης και χρησης αυτων
NO920945D0 (no) Nye 8-substituerte puriner som selektive adenosinreseptormidler
CA2275686A1 (en) Isoquinolinamine and phthalazinamine derivatives which interact with crf receptors
ATE256126T1 (de) 5-heteroatom-alkyl substituierte 3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid derivate zur behandlung zentral nervöser system störungen
PT889044E (pt) Derivados do 5-(heteroaril)alquil-3-oxo-pirido-(1,2-a)benzimidazole-4-carboxamida (pbi) uteis no tratamento de perturbacoes do sistema nervoso central
ATE321044T1 (de) C-6 ringsubstituierte pyrido(1,2- a)benzimidazolderivate zur behandlung von störungen des zentralen nervensystems
NO20053612D0 (no) 1,2,4-triaminobenzenderivater nyttige for behandling av forstyrrelser i sentralnervesystemet